Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 4 1

Status

Completed 3Unknown 2

Sponsor Class

OTHER 23INDUSTRY 5OTHER_GOV 4

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 5Sarcoma 1Lymphoid 1Gastrointestinal 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Small Cell Lung Carcinoma 1Pleural Effusion, Malignant 1

Interventions

Carboplatin 542Pemetrexed 392pembrolizumab 372Cisplatin 356Paclitaxel 285Docetaxel 240Gemcitabine 168Nivolumab 158Erlotinib Hydrochloride 147Bevacizumab 114atezolizumab 104osimertinib 99durvalumab 92Etoposide 90Gefitinib 68130-nm albumin-bound paclitaxel 65Cetuximab 64Ipilimumab 60Drug Therapy 51Topotecan 48Injections 44Afatinib 41tislelizumab 40Cyclophosphamide 39Albumin-Bound Paclitaxel 37Vinorelbine 36Crizotinib 34cemiplimab 31icotinib 26Radiotherapy 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × endostar protein × Thoracic × Clear all
NCT04942301 2021-06-30

PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 1 Unknown
24 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02513355 2015-08-04

Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research

Nanjing NingQi Medicine Science and Technology Co., Ltd.

Phase 4 Unknown
400 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00912392 2014-09-03

Etoposide-Carboplatin Alone or With Endostar for Extensive Disease Small Cell Lung Cancer (ED-SCLC)

Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd

Phase 2 Completed
138 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT01327235 2014-08-01

Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 2 Completed
336 enrolled
Thoracic

Pleural Effusion, Malignant

NCT01531790 2013-01-16

A Study of Continuous Endostar Intravenous Infusion Combined With Pemetrexed and Carboplatin in Advanced Non Small Cell Lung Cancer Patients

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 1 Completed
19 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡